Altamira Therapeutics (NASDAQ:CYTO) completed patient enrollment with its Bentrio nasal spray in a house dust mite allergic rhinitis trial and expects to release top-line results from the trial during the second quarter of 2022.
The trial, which enrolled a total of 37 patients with a history of perennial allergic rhinitis caused by house dust mite exposure, is designed to evaluate the efficacy of Bentrio in the treatment of perennial allergic rhinitis in an environmental exposure chamber, under controlled house dust mite exposure.
Study participants were randomized under an open label, three-period crossover design to receive either Bentrio in a single or double dose or no treatment prior to house dust mite exposure for three hours. The primary endpoint will be the change in the total nasal symptom score from baseline. The trial is being conducted at a single study site in Canada.
In a statement, Thomas Meyer, founder, chairman and CEO of Altamira, said house dust mite allergies are a very common problem, especially in more humid geographies, and can cause serious suffering and reduced quality of life
“Following the positive outcomes from our previous clinical investigation of Bentrio in grass pollen allergic rhinitis, we expect this new study to add to the growing body of evidence demonstrating Bentrio’s protective effects against multiple airborne allergens,” he added.
In addition, Mr. Meyer said Altamira is continuing the commercial roll-out of Bentrio, helping to provide relief for many allergy sufferers who have been looking for an effective treatment without any drug or preservative ingredients.
